1
Magnevist Post-marketing Surveillance in Japan
Condition(s):Diagnostic ImagingLast Updated:June 20, 2011Completed
Magnevist: 123 Clinical Trials, Page 1 of 13
Hide Studies Not Open or Pending
2
Multihance at 3 Tesla (3T) in Brain Tumors
Condition(s):Brain TumorLast Updated:November 5, 2020Completed
3
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Condition(s):Fibrosis; Kidney Failure; Renal InsufficiencyLast Updated:September 22, 2014Completed
4
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
Condition(s):Central Nervous System Diseases; Central Nervous System NeoplasmsLast Updated:July 18, 2018Completed
5
Contrast-enhanced MRI in Children 2 Months to <2 Years
Condition(s):Magnetic Resonance ImagingLast Updated:November 18, 2015Completed
6
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Condition(s):Magnetic Resonance Angiography; Peripheral Vascular Diseases; Peripheral Arterial DiseasesLast Updated:October 14, 2013Completed
7
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
Condition(s):Brain NeoplasmsLast Updated:December 15, 2014Completed
8
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Condition(s):Liver TumorLast Updated:January 13, 2017Completed
9
Safety and Efficacy of MultiHance in Pediatric Patients
Condition(s):Central Nervous System DiseasesLast Updated:October 22, 2010Terminated
10
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Condition(s):Peripheral Vascular DiseaseLast Updated:December 30, 2014Completed